PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAsenapine
Saphris, Sycrest(asenapine)
Asenapine, Saphris, Secuado, Sycrest (asenapine) is a small molecule pharmaceutical. Asenapine was first approved as Saphris on 2009-08-13. It is used to treat bipolar disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat bipolar disorder. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A and D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 1D, histamine H1 receptor, 5-hydroxytryptamine receptor 1E, and 5-hydroxytryptamine receptor 1A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
mental disordersD001523
Trade Name
FDA
EMA
Asenapine, Saphris, Secuado
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Asenapine maleate
Tradename
Company
Number
Date
Products
SAPHRISAllerganN-022117 RX2009-08-13
3 products, RLD, RS
Asenapine
Tradename
Company
Number
Date
Products
SECUADOHisamitsu PharmaceuticalN-212268 RX2019-10-11
3 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
asenapineANDA2024-02-13
saphrisNew Drug Application2025-01-31
secuadoNew Drug Application2025-01-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
schizophreniaEFO_0000692D012559F20
bipolar disorderEFO_0000289D001714F30.9
schizophrenia spectrum and other psychotic disorders—D019967—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Asenapine, Secuado, Hisamitsu
118133642033-09-22DP
96874742033-07-25DP
100224452033-07-25DP
105831212033-07-25DPU-2763
108140022033-07-25DPU-2763
111233052033-07-25DP
Asenapine Maleate, Saphris, Allergan
77413582026-04-06DS, DPU-1064, U-1893, U-1960, U-1961, U-1962, U-1963, U-1966
80222282026-04-06DS, DP
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AH: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
— N05AH05: Asenapine
HCPCS
No data
Clinical
No data
Drug
General
Drug common nameAsenapine
INNasenapine
Description
(S,S)-asenapine is a 5-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole in which both of the stereocentres have S configuration. It is a conjugate base of a (S,S)-asenapine(1+). It is an enantiomer of a (R,R)-asenapine.
Classification
Small molecule
Drug classtricyclic compounds
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1
Identifiers
PDB—
CAS-ID65576-45-6
RxCUI784649
ChEMBL IDCHEMBL3187365
ChEBI ID71255
PubChem CID163091
DrugBankDB06216
UNII IDJKZ19V908O (ChemIDplus, GSRS)
Target
Agency Approved
HTR2A
HTR2A
DRD2
DRD2
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
3356
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Q5T8C0
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Alternate
HTR1B
HTR1B
HTR1D
HTR1D
HRH1
HRH1
HTR1E
HTR1E
HTR1A
HTR1A
Organism
Homo sapiens
Gene name
HTR1B
Gene synonyms
HTR1DB
NCBI Gene ID
3351
Protein name
5-hydroxytryptamine receptor 1B
Protein synonyms
5-HT-1D-beta, 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled, S12, Serotonin 1D beta receptor, Serotonin receptor 1B
Uniprot ID
Q4VAY7
Mouse ortholog
Htr1b (15551)
5-hydroxytryptamine receptor 1B (P28334)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Saphris – Allergan
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Saphris – Warner Chilcott
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Asenapine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
Black-box warning for: Asenapine, Saphris, Secuado
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use